738 related articles for article (PubMed ID: 16129848)
21. Treatment outcomes in adults with favorable histologic type Wilms tumor-an update from the National Wilms Tumor Study Group.
Kalapurakal JA; Nan B; Norkool P; Coppes M; Perlman E; Beckwith B; Ritchey M; Breslow N; Grundy P; D'angio GJ; Green DM; Thomas PR
Int J Radiat Oncol Biol Phys; 2004 Dec; 60(5):1379-84. PubMed ID: 15590168
[TBL] [Abstract][Full Text] [Related]
22. Identification of a minimal region of loss on the short arm of chromosome 1 in Wilms tumor.
Tamimi Y; Ziebart K; Desaulniers N; Dietrich K; Grundy P
Genes Chromosomes Cancer; 2007 Apr; 46(4):327-35. PubMed ID: 17243164
[TBL] [Abstract][Full Text] [Related]
23. Clonality and loss of heterozygosity of WT genes are early events in the pathogenesis of nephroblastomas.
Guertl B; Ratschek M; Harms D; Jaenig U; Leuschner I; Poremba C; Hoefler G
Hum Pathol; 2003 Mar; 34(3):278-81. PubMed ID: 12673563
[TBL] [Abstract][Full Text] [Related]
24. Increased microvascular density predicts relapse in Wilms' tumor.
Abramson LP; Grundy PE; Rademaker AW; Helenowski I; Cornwell M; Katzenstein HM; Reynolds M; Arensman RM; Crawford SE
J Pediatr Surg; 2003 Mar; 38(3):325-30; discussion 325-30. PubMed ID: 12632343
[TBL] [Abstract][Full Text] [Related]
25. Augmentation of Therapy for Combined Loss of Heterozygosity 1p and 16q in Favorable Histology Wilms Tumor: A Children's Oncology Group AREN0532 and AREN0533 Study Report.
Dix DB; Fernandez CV; Chi YY; Mullen EA; Geller JI; Gratias EJ; Khanna G; Kalapurakal JA; Perlman EJ; Seibel NL; Ehrlich PF; Malogolowkin M; Anderson J; Gastier-Foster J; Shamberger RC; Kim Y; Grundy PE; Dome JS;
J Clin Oncol; 2019 Oct; 37(30):2769-2777. PubMed ID: 31449468
[TBL] [Abstract][Full Text] [Related]
26. Pediatric genitourinary tumors.
Castellino SM; McLean TW
Curr Opin Oncol; 2007 May; 19(3):248-53. PubMed ID: 17414644
[TBL] [Abstract][Full Text] [Related]
27. Effect of duration of treatment on treatment outcome for patients with clear-cell sarcoma of the kidney: a report from the National Wilms' Tumor Study Group.
Seibel NL; Li S; Breslow NE; Beckwith JB; Green DM; Haase GM; Ritchey ML; Thomas PR; Grundy PE; Finklestein JZ; Kim T; Shochat SJ; Kelalis PP; D'Angio GJ
J Clin Oncol; 2004 Feb; 22(3):468-73. PubMed ID: 14752069
[TBL] [Abstract][Full Text] [Related]
28. Microdissecting the genetic events in nephrogenic rests and Wilms' tumor development.
Charles AK; Brown KW; Berry PJ
Am J Pathol; 1998 Sep; 153(3):991-1000. PubMed ID: 9736048
[TBL] [Abstract][Full Text] [Related]
29. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors.
Gicquel C; Bertagna X; Gaston V; Coste J; Louvel A; Baudin E; Bertherat J; Chapuis Y; Duclos JM; Schlumberger M; Plouin PF; Luton JP; Le Bouc Y
Cancer Res; 2001 Sep; 61(18):6762-7. PubMed ID: 11559548
[TBL] [Abstract][Full Text] [Related]
30. Loss of heterozygosity at D8S298 is a predictor for long-term survival of patients with tumor-node-metastasis stage I of hepatocellular carcinoma.
Pang JZ; Qin LX; Ren N; Hei ZY; Ye QH; Jia WD; Sun BS; Lin GL; Liu DY; Liu YK; Tang ZY
Clin Cancer Res; 2007 Dec; 13(24):7363-9. PubMed ID: 18094418
[TBL] [Abstract][Full Text] [Related]
31. Der(16)t(1;16)(q21;q13) in Wilms' tumor: friend or foe.
Mathew P; Douglass EC; Jones D; Valentine M; Valentine V; Rowe S; Shapiro DN
Med Pediatr Oncol; 1996 Jul; 27(1):3-7. PubMed ID: 8614388
[TBL] [Abstract][Full Text] [Related]
32. Loss of heterozygosity in Wilms' tumors, studied for six putative tumor suppressor regions, is limited to chromosome 11.
Mannens M; Devilee P; Bliek J; Mandjes I; de Kraker J; Heyting C; Slater RM; Westerveld A
Cancer Res; 1990 Jun; 50(11):3279-83. PubMed ID: 2159377
[TBL] [Abstract][Full Text] [Related]
33. High telomerase RNA expression level is an adverse prognostic factor for favorable-histology Wilms' tumor.
Dome JS; Bockhold CA; Li SM; Baker SD; Green DM; Perlman EJ; Hill DA; Breslow NE
J Clin Oncol; 2005 Dec; 23(36):9138-45. PubMed ID: 16172460
[TBL] [Abstract][Full Text] [Related]
34. Loss of heterozygosity at 7p in Wilms' tumour development.
Powlesland RM; Charles AK; Malik KT; Reynolds PA; Pires S; Boavida M; Brown KW
Br J Cancer; 2000 Jan; 82(2):323-9. PubMed ID: 10646884
[TBL] [Abstract][Full Text] [Related]
35. [Treatment strategy for children with Wilms tumor].
Fukuzawa M
Nihon Geka Gakkai Zasshi; 2005 Jul; 106(7):422-6. PubMed ID: 16045185
[TBL] [Abstract][Full Text] [Related]
36. Genome-wide loss of heterozygosity analysis of WT1-wild-type and WT1-mutant Wilms tumors.
Ruteshouser EC; Hendrickson BW; Colella S; Krahe R; Pinto L; Huff V
Genes Chromosomes Cancer; 2005 Jun; 43(2):172-80. PubMed ID: 15761866
[TBL] [Abstract][Full Text] [Related]
37. Association of 11q loss, trisomy 12, and possible 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor.
Watanabe N; Nakadate H; Haruta M; Sugawara W; Sasaki F; Tsunematsu Y; Kikuta A; Fukuzawa M; Okita H; Hata J; Soejima H; Kaneko Y
Genes Chromosomes Cancer; 2006 Jun; 45(6):592-601. PubMed ID: 16518847
[TBL] [Abstract][Full Text] [Related]
38. High frequency of loss of heterozygosity for 1p35-p36 (D1S247) in Wilms tumor.
Steinberg R; Freud E; Zer M; Ziperman I; Goshen Y; Ash S; Stein J; Zaizov R; Avigad S
Cancer Genet Cytogenet; 2000 Mar; 117(2):136-9. PubMed ID: 10704684
[TBL] [Abstract][Full Text] [Related]
39. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors.
McDonald JM; See SJ; Tremont IW; Colman H; Gilbert MR; Groves M; Burger PC; Louis DN; Giannini C; Fuller G; Passe S; Blair H; Jenkins RB; Yang H; Ledoux A; Aaron J; Tipnis U; Zhang W; Hess K; Aldape K
Cancer; 2005 Oct; 104(7):1468-77. PubMed ID: 16088966
[TBL] [Abstract][Full Text] [Related]
40. [Wilms' tumor: reached progress and future prospects].
Tamaro P
Arch Ital Urol Androl; 1997 Sep; 69(4):227-32. PubMed ID: 9417294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
